Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APM Aptorum Group	$1.00 -0.5%	$0.97	$0.46 ▼ $7.49	$5.35M	-0.14	619,627 shs	35,759 shs
CRDL Cardiol Therapeutics	$1.47 +1.4%	$1.21	$0.77 ▼ $2.63	$119.84M	1.03	310,613 shs	142,827 shs
GXE Gear Energy		C$0.50	C$0.45 ▼ C$0.80	C$126.52M	3.52	585,822 shs	1.03 million shs
VIR Vir Biotechnology	$5.31 +2.3%	$5.27	$4.32 ▼ $14.45	$717.46M	1.24	1.36 million shs	772,437 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APM Aptorum Group	+2.64%	-3.78%	+12.70%	+14.89%	-78.93%
CRDL Cardiol Therapeutics	+8.21%	+9.85%	+31.82%	+46.46%	-31.60%
GXE Gear Energy	0.00%	0.00%	0.00%	0.00%	-29.41%
VIR Vir Biotechnology	-1.52%	-0.38%	+15.33%	-22.19%	-43.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APM Aptorum Group	1.1215 of 5 stars	0.0	3.0	0.0	0.0	3.3	1.7	0.6
CRDL Cardiol Therapeutics	2.4867 of 5 stars	3.7	2.0	0.0	0.0	4.0	0.0	0.6
GXE Gear Energy	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	3.2265 of 5 stars	3.4	1.0	0.0	0.0	3.7	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APM Aptorum Group	0.00	N/A	N/A	N/A
CRDL Cardiol Therapeutics	3.33	Buy	$8.00	444.22% Upside
GXE Gear Energy	2.00	Hold	N/A	N/A
VIR Vir Biotechnology	2.86	Moderate Buy	$32.86	518.78% Upside

Current Analyst Ratings Breakdown

Latest VIR, CRDL, APM, and GXE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
5/22/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
5/12/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$19.00 ➝ $14.00
4/17/2025	VIR Vir Biotechnology	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $21.00
4/16/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/7/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00

(Data available from 6/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APM Aptorum Group	$430K	12.39	N/A	N/A	$2.20 per share	0.45
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.22 per share	N/A
GXE Gear Energy	C$134.93M	0.00	N/A	540.00	C$0.93 per share	0.00
VIR Vir Biotechnology	$74.21M	9.89	N/A	N/A	$8.35 per share	0.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APM Aptorum Group	-$4.27M	N/A	0.00	∞	N/A	N/A	N/A	N/A	7/30/2025 (Estimated)
CRDL Cardiol Therapeutics	-$26.77M	-$0.34	N/A	N/A	N/A	N/A	-209.63%	-141.09%	7/14/2025 (Estimated)
GXE Gear Energy	C$13.02M	C$0.05	10.39	N/A	N/A	8.53%	5.08%	4.84%	N/A
VIR Vir Biotechnology	-$521.96M	-$4.22	N/A	N/A	N/A	-2,769.04%	-47.46%	-39.33%	7/30/2025 (Estimated)

Latest VIR, CRDL, APM, and GXE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/7/2025	Q1 2025	VIR Vir Biotechnology	-$0.83	-$0.88	-$0.05	-$0.88	$8.59 million	$3.03 million
3/31/2025	Q4 2024	CRDL Cardiol Therapeutics	-$0.08	-$0.07	+$0.01	-$0.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APM Aptorum Group	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
GXE Gear Energy	C$0.06	11.46%	N/A	120.00%	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APM Aptorum Group	N/A	0.22	0.22
CRDL Cardiol Therapeutics	0.01	3.26	3.26
GXE Gear Energy	6.27	1.20	0.56
VIR Vir Biotechnology	N/A	6.79	6.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APM Aptorum Group	3.80%
CRDL Cardiol Therapeutics	12.49%
GXE Gear Energy	2.42%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
APM Aptorum Group	63.99%
CRDL Cardiol Therapeutics	5.25%
GXE Gear Energy	7.62%
VIR Vir Biotechnology	16.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APM Aptorum Group	30	5.35 million	1.93 million	Not Optionable
CRDL Cardiol Therapeutics	20	82.65 million	78.31 million	Not Optionable
GXE Gear Energy	1,310	263.58 million	N/A	Not Optionable
VIR Vir Biotechnology	580	138.24 million	116.12 million	Optionable

VIR, CRDL, APM, and GXE Headlines

Recent News About These Companies

Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?

June 25 at 2:30 PM | finance.yahoo.com

Brokerages Set Vir Biotechnology, Inc. (NASDAQ:VIR) Target Price at $32.86

June 17, 2025 | americanbankingnews.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by Brokerages

June 12, 2025 | marketbeat.com

Bank of America Corp DE Has $1.42 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)

June 6, 2025 | marketbeat.com

Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells 3,200 Shares of Stock

June 3, 2025 | marketbeat.com

Janet Napolitano Sells 3,200 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

June 3, 2025 | insidertrades.com

Nuveen Asset Management LLC Has $2.64 Million Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)

June 3, 2025 | marketbeat.com

Vir Biotechnology (NASDAQ:VIR) Stock Price Down 7.6% - Here's What Happened

May 31, 2025 | marketbeat.com

Vir Biotechnology (NASDAQ:VIR) Trading 6.6% Higher - What's Next?

May 30, 2025 | marketbeat.com

Vir Biotech at TD Cowen’s Summit: Strategic Focus on HDV and Oncology

May 29, 2025 | investing.com

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 28, 2025 | businesswire.com

Voloridge Investment Management LLC Lowers Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

May 28, 2025 | marketbeat.com

Woodline Partners LP Makes New $991,000 Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)

May 28, 2025 | marketbeat.com

Millennium Management LLC Has $12.59 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

May 26, 2025 | marketbeat.com

Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs

May 22, 2025 | fiercebiotech.comF

Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

May 22, 2025 | benzinga.com

Vir’s hepatitis B combo falls short in Phase II trial

May 12, 2025 | msn.com

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 12, 2025 | businesswire.com

Vir Biotechnology First Quarter 2025 Earnings: Revenues Disappoint

May 10, 2025 | finance.yahoo.com

Why Vir Biotechnology, Inc.’s (VIR) Stock Is Down 5.45%

May 10, 2025 | aaii.comA

Q1 2025 Vir Biotechnology Inc Earnings Call

May 10, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
3 Tech Stocks You Can't Miss in This Market Cycle
By Gabriel Osorio-Mazilli | June 17, 2025
View 3 Tech Stocks You Can't Miss in This Market Cycle
AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed
By Thomas Hughes | June 25, 2025
View AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed

VIR, CRDL, APM, and GXE Company Descriptions

Aptorum Group NASDAQ:APM

$1.00 0.00 (-0.47%)

Closing price 03:40 PM Eastern

Extended Trading

$1.00 0.00 (0.00%)

As of 06:32 PM Eastern

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

Cardiol Therapeutics NASDAQ:CRDL

$1.47 +0.02 (+1.38%)

Closing price 04:00 PM Eastern

Extended Trading

$1.47 0.00 (0.00%)

As of 06:39 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Gear Energy TSE:GXE

Gear Energy Ltd., an exploration and production company, engages in the acquiring, developing, and holding of interests in petroleum and natural gas properties and assets in Canada. The company's oil properties are located in Central Alberta, West Central Saskatchewan, and Southeast Saskatchewan. Gear Energy Ltd. is headquartered in Calgary, Canada.

Vir Biotechnology NASDAQ:VIR

$5.31 +0.12 (+2.31%)

Closing price 04:00 PM Eastern

Extended Trading

$5.24 -0.07 (-1.41%)

As of 07:41 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time